Vericel websites use cookies, small text files stored on your browser, to personalize your web experience and to analyze website traffic. By continuing to use this website without changing your settings, you are agreeing to our use of cookies and to our collection of information. For more information about what Vericel collects and how we use it, visit our Privacy Policy.
CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023.
CAMBRIDGE, Mass. , Oct. 23, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2018 financial results and
CAMBRIDGE, Mass., Oct. 22, 2019 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2019 financial results and business
CAMBRIDGE, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2020 financial results and business
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its third-quarter 2021 financial results and business
CAMBRIDGE, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2022 financial results on Wednesday, November 9, 2022.
CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its third-quarter 2023 financial results on Wednesday, November 8, 2023.
Warren Chaunce Bogard, Jr., Ph.D. Appointed to Aastrom Biosciences' Board of Directors Ann Arbor, Michigan, February 4, 2005 -- Aastrom Biosciences, Inc. (NasdaqSC: ASTM) announced today that Warren Chaunce Bogard, Jr., Ph.D. has been appointed to the Company's Board of Directors.
ANN ARBOR, Mich., Oct 16, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. Conference Call to Discuss the Results from the U.S. Phase I/II Severe Fracture Trial When: Monday, October 22, 2007 at 9:00 am (EDT) Where:
ANN ARBOR, Mich., Nov 05, 2007 (BUSINESS WIRE) -- Aastrom Biosciences, Inc. (NASDAQ: ASTM) announces the following Webcast: What: Aastrom Biosciences, Inc. First Quarter Fiscal Year 2008 Investor Conference Call When: Friday, November 9, 2007 @ 9:00 am (Eastern) Where: